Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Imunon ( (IMNN) ) just unveiled an announcement.
Imunon, Inc. has received a delisting determination from Nasdaq due to non-compliance with the minimum bid price and stockholders’ equity requirements. The company plans to appeal the decision and may implement a reverse stock split to regain compliance, but there is no assurance of success. Delisting could impact stock trading and capital raising.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Average Trading Volume: 9,572,535
Technical Sentiment Signal: Buy
Current Market Cap: $34.91M
For detailed information about IMNN stock, go to TipRanks’ Stock Analysis page.